Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib

被引：17

作者：

Zhou, Amy ^{[1
]}

Kong, Tim ^{[1
]}

Fowles, Jared S. ^{[1
]}

Jung, Chun-Ling ^{[2
]}

Allen, Maggie J. ^{[1
]}

Fisher, Daniel A. C. ^{[1
]}

Fulbright, Mary ^{[1
]}

Nemeth, Elizabeta ^{[2
]}

Ganz, Tomas ^{[2
]}

Oh, Stephen T. ^{[1
]}

机构：

[1] Washington Univ, St Louis, MO 63110 USA

[2] Univ Calif Los Angeles, Los Angeles, CA 90024 USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 197卷 / 04期

关键词：

THERAPY; ANEMIA;

D O I：

10.1111/bjh.18044

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E49 / E52

页数：4

共 13 条

[1] Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents [J].

Asshoff, Malte ;

Petzer, Verena ;

Warr, Matthew R. ;

Haschka, David ;

Tymoszuk, Piotr ;

Demetz, Egon ;

Seifert, Markus ;

Posch, Wilfried ;

Nairz, Manfred ;

Maciejewski, Pat ;

Fowles, Peter ;

Burns, Christopher J. ;

Smith, Gregg ;

Wagner, Kay-Uwe ;

Weiss, Guenter ;

Whitney, J. Andrew ;

Theurl, Igor .

BLOOD, 2017, 129 (13) :1823-1830

[2] The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion [J].

Barbui, Tiziano ;

Thiele, Jurgen ;

Gisslinger, Heinz ;

Kvasnicka, Hans Michael ;

Vannucchi, Alessandro M. ;

Guglielmelli, Paola ;

Orazi, Attilio ;

Tefferi, Ayalew .

BLOOD CANCER JOURNAL, 2018, 8 :15

[3] Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group [J].

Birgegard, Gunnar ;

Samuelsson, Jan ;

Ahlstrand, Erik ;

Ejerblad, Elisabeth ;

Enevold, Christian ;

Ghanima, Waleed ;

Hasselbalch, Hans ;

Nielsen, Claus H. ;

Knutsen, Havar ;

Pedersen, Ole B. ;

Sorensen, Anders ;

Andreasson, Bjorn .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2019, 102 (03) :235-240

[4] Prognostication in Primary Myelofibrosis [J].

Cervantes, Francisco ;

Pereira, Arturo .

CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2012, 7 (01) :43-49

[5] Immunoassay for human serum erythroferrone [J].

Ganz, Tomas ;

Jung, Grace ;

Naeim, Arash ;

Ginzburg, Yelena ;

Pakbaz, Zahra ;

Walter, Patrick B. ;

Kautz, Leon ;

Nemeth, Elizabeta .

BLOOD, 2017, 130 (10) :1243-1246

[6] Hepcidin and iron homeostasis [J].

Ganz, Tomas ;

Nemeth, Elizabeta .

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2012, 1823 (09) :1434-1443

[7] JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis [J].

Harrison, Claire ;

Kiladjian, Jean-Jacques ;

Al-Ali, Haifa Kathrin ;

Gisslinger, Heinz ;

Waltzman, Roger ;

Stalbovskaya, Viktoriya ;

McQuitty, Mari ;

Hunter, Deborah S. ;

Levy, Richard ;

Knoops, Laurent ;

Cervantes, Francisco ;

Vannucchi, Alessandro M. ;

Barbui, Tiziano ;

Barosi, Giovanni .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (09) :787-798

[8] Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization [J].

Nemeth, E ;

Tuttle, MS ;

Powelson, J ;

Vaughn, MB ;

Donovan, A ;

Ward, DM ;

Ganz, T ;

Kaplan, J .

SCIENCE, 2004, 306 (5704) :2090-2093

[9] ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial [J].

Oh, Stephen T. ;

Talpaz, Moshe ;

Gerds, Aaron T. ;

Gupta, Vikas ;

Verstovsek, Srdan ;

Mesa, Ruben ;

Miller, Carole B. ;

Rivera, Candido E. ;

Fleischman, Angela G. ;

Goel, Swati ;

Heaney, Mark L. ;

O'Connell, Casey ;

Arcasoy, Murat O. ;

Zhang, Yafeng ;

Kawashima, Jun ;

Ganz, Tomas ;

Kowalski, Mark ;

Brachmann, Carrie Baker .

BLOOD ADVANCES, 2020, 4 (18) :4282-4291

[10] Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis [J].

Pardanani, Animesh ;

Finke, Christy ;

Abdelrahman, Ramy A. ;

Lasho, Terra L. ;

Tefferi, Ayalew .

AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (04) :312-316

← 1 2 →